Michael Bigham - Dec 13, 2021 Form 4 Insider Report for Paratek Pharmaceuticals, Inc. (PRTK)

Role
Exec. Chairman of the Board, Director
Signature
/s/ William M. Haskel, Attorney-in-Fact for Michael Bigham
Stock symbol
PRTK
Transactions as of
Dec 13, 2021
Transactions value $
-$136,126
Form type
4
Date filed
12/15/2021, 08:02 PM
Previous filing
Nov 24, 2021
Next filing
Mar 23, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PRTK Common Stock Sale -$22.4K -5.06K -0.55% $4.42 917K Dec 13, 2021 Direct F1, F2
transaction PRTK Common Stock Sale -$37.7K -8.62K -0.94% $4.37 909K Dec 14, 2021 Direct F1, F3
transaction PRTK Common Stock Sale -$76.1K -17.8K -1.96% $4.27 891K Dec 15, 2021 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Sale of shares to cover personal income tax obligations upon vesting of restricted stock unit award, pursuant to a Rule 10b5-1 trading plan.
F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $4.31 to $4.52. The Reporting Person undertakes to provide to Paratek Pharmaceuticals, Inc., any security holder of Paratek Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 2 to this Form 4
F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $4.20 to $4.48. The Reporting Person undertakes to provide to Paratek Pharmaceuticals, Inc., any security holder of Paratek Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 3 to this Form 4.
F4 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $4.11 to $4.34. The Reporting Person undertakes to provide to Paratek Pharmaceuticals, Inc., any security holder of Paratek Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 4 to this Form 4.